An exploratory study of MCI-196 [colestilan] for treatment of type 2 diabetes in randomized, double blind, parallel assignment, placebo-controlled manner

Trial Profile

An exploratory study of MCI-196 [colestilan] for treatment of type 2 diabetes in randomized, double blind, parallel assignment, placebo-controlled manner

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2011

At a glance

  • Drugs Colestilan (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Pharma Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2010 Secondary endpoint 'Low density lipoprotein cholesterol level' has been met according to results published in Diabetes, Obesity and Metabolism.
    • 01 Mar 2010 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met according to results published in Diabetes, Obesity and Metabolism,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top